AKLRD at OARSI 2022

Presentation of the results from the Phase 2a osteoarthritis trial of AKLRD’s lead candidate, APPA, and ALKRD’s sponsorship of OARSI’s Rising Star Awards are two of the reasons AKLRD’s representatives are delighted to be attending OARSI 2022. It is the first time in 2 years that it has been possible to attend, in person, this […]

Read More

Senescence Research in APPA with INIBIC

AKLRD has agreed a further collaboration with the Institute of Biomedical Research of A Coruña (INIBIC) to advance the understanding of APPA’s mechanism of action.  INIBIC is Spain’s leading biomedical research institution. Previous research at INIBIC has shown that APPA has a significant effect on senescent cells in human chondrocytes1 – see BMJ abstract. This […]

Read More

Completion of Phase 2a Human Trial

AKL Research and Development (AKLRD) has recently completed a Phase 2a, 28-day 150 patient, trial of oral APPA in osteoarthritis (OA) of the knee The data from this Phase 2a trial adds considerably to our understanding of APPA. It advances our ability to select the patients most likely to benefit from APPA. Key Findings from […]

Read More

MHRA awards Innovation Passport for APPA in Osteoarthritis

Following consideration by MHRA, NICE, and SMC, the Innovative Licensing and Access Pathway Steering Group has informed AKL Research & Development Ltd that the innovative medicine designation, the Innovation Passport, has been awarded for APPA in the treatment of osteoarthritis. The Innovation Passport is the entry point to the Innovative Licensing and Access Pathway (ILAP) […]

Read More